FDA Clearance Tracker · P130021-S051
CoreValve Evolut R System and CoreValve Evolut PRO System
Last checked: Nov 20, 2026Latest source record: Aug 24, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Aug 24, 2018
Approved
Time to decision
56 days
Received Jun 29, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P130021-S051
- Device name
- CoreValve Evolut R System and CoreValve Evolut PRO System
- Applicant
- Medtronic, Inc.
- Applicant location
- Miinneapolis, MN
- Received
- Jun 29, 2018
- Decided
- Aug 24, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130021
Device type
- Device class
- Class III
- Specialty
- CardiologyInterventional Cardiology
FDA's approval statement
As written in FDA's record.
Approval for modifying the labeling to remove the precaution regarding patients with a congenital bicuspid aortic valve.
Source documents
Other decisions for Medtronic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K263596 · Decided Oct 29, 2026 · 29 days after receipt
Device type: Catheter, Cannula And Tubing, Vascular, Cardiopulmonary Bypass (DWF) · Cardiology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.